30 closest matches · ranked by relevance
Skin/Soft Tissue Infections · Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…
Skin Diseases, Infectious · Soft Tissue Infections
Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71
Abscess
Primary: Number of Participants With Abscess Resolution — 11; 9 Participants
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
Abscess
Primary: Sensitivity and Specificity of Bedside Emergency Ultrasound When Added to the Clinical Examination Compared With Clinical Examination Alone. — 94.7; 93.1; 84.2; 81.4…
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Skin and Subcutaneous Tissue Bacterial Infections · Skin Structures and Soft Tissue Infections
Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…
Staphylococcal Infection
Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants
Acute Bacterial Skin and Skin Structure Infections
Primary: Early Clinical Response — 306; 303 Participants
Diabetes · Wound Infection · Healthy Volunteers
Primary: Tedizolid Tissue Penetration — 0.98; 0.82 ratio
Cellulitis · Skin Infections
Primary: Satisfaction of Discharge Criteria — 15; 14 participants
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Skin and Soft Tissue (SST) Infection
Primary: Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day — 43305; 40156; 43927; 30287 Extended-Spectrum Days-of-Therapy
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
Complicated Skin and Soft Tissue Infection
Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant
Staphylococcal Skin Infection
Primary: Clinical Response — 323; 321; 52; 58 participants
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Objective Response at 48 to 72 Hours (FDA Primary Endpoint) — 259; 266; 72; 63 Participants
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Staphylococcal Skin Infection
Primary: Clinical Response — 358; 364; 59; 57 patients
Pressure Ulcers
Primary: Transepidermal Water Loss (TEWL) in g/m2/h on Sacrum, at Baseline — 7.8; 7.7; 7.1 g/m2/h
Infections, Gram-Positive Bacterial · Abscess · Burns
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 66; 66; 6; 3 participants — p=0.5289
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
Skin Diseases, Infectious
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 36.1; 36.8; 23.3; 18.4 percentage of participants
Bacterial Infections · Acute Bacterial Skin and Skin Structure Infection
Primary: Number of Infection-related Total Admitted Hospital Days — 4.8; 3.2 Days — p=0.003
Surgical Site Infection
Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants
Furunculosis
Primary: Number of Side-effects — 4; 2 Participants
Skin Diseases, Infectious
Primary: Skin Abscess Resolution — 4; 3 participants